Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001649553-25-000062
Filing Date
2025-05-01
Accepted
2025-05-01 10:01:03
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9414
2 LIMITED POWER OF ATTORNEY sc13g_ex24.htm EX-24 2382
3 JOINT FILING AGREEMENT bctx_sc13g-ex99.htm EX-99 1629
  Complete submission text file 0001649553-25-000062.txt   15250
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Subject) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92289 | Film No.: 25900120
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Business Address P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 345-949-8080
CVI Investments, Inc. (Filed by) CIK: 0001649553 (see all company filings)

EIN.: 981253664 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G